The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
Nilanjana Das, PhD
Advertisement
Nilanjana Das, PhD, is a senior research investigator at Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, US, nila.das@bms.com.
Articles by Nilanjana Das, PhD
Advertisement
Latest Updated Articles
Commercializing High-Concentration mAbsPublished: November 1st 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
4
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
5
